Brief: U.S. FDA Approves Rybrevant Faspro™ For The Treatment Of Advanced EGFR-Mutated Non-Small Cell Lung Cancer
18/12/2025 12:09
Dec 18 (Reuters) - Halozyme Therapeutics Inc HALO.O: U.S. FDA APPROVES RYBREVANT FASPRO™ (AMIVANTAMAB AND HYALURONIDASE-LPUJ) CO-FORMULATED WITH ENHANZE® FOR THE TREATMENT OF ADVANCED EGFR-MUTATED NON-SMALL CELL LUNG CANCER Source text: ID:nPn90ykSGa Further company coverage: HALO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Halozyme Therapeutics
See all newsUS RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)
US STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
Halozyme wins court order to block Merck's injected Keytruda in select European markets